BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 29, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Regulatory actions for Dec. 9, 2022

Dec. 9, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akero, Bioxytran, Bloomsbury Genetic, Brim, Cerecin, Emmaus, In8bio, Liscure, Moderna, Molecular Targeting, Numinus, Quralis, Takeda, VBI, Visiox, Y-mabs.
Read More

In the clinic for Dec. 9, 2022

Dec. 9, 2022

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aim, Anixa, Baudaxbio, Celcuity, Clinigen, Compass, Createrna, Daiichi Sankyo, Design, Diamond, Dragonfly, Federation, Horizon, Ionctura, Kronos, Novadip, Phavaris, Regenxbio, Spago, Spinethera.


Read More
Infection

CSPC's small-molecule 3CLpro inhibitor SYH-2055 cleared for clinical trials in China

Dec. 9, 2022
CSPC Pharmaceutical Group Ltd. has obtained clearance from China's National Medical Products Administration (NMPA) to conduct clinical trials in China with SYH-2055, an oral small-molecule 3C-like protease (3CLpro) inhibitor against SARS-CoV-2.
Read More
SARS-CoV-2-hero-BWS.png
Infection

Targeting bile acid receptor could help prevent SARS-CoV-2 infection

Dec. 9, 2022
By Nuala Moran
New research has identified a novel receptor that interacts with the angiotensin-converting enzyme 2 (ACE2) by which the SARS-CoV-2 enters host cells, and shown it can be inhibited with marketed drugs, reducing expression of ACE2 and blocking viral entry.
Read More

China grants emergency use of new vaccines as it eases COVID-19 policy

Dec. 8, 2022
By Doris Yu
China recently approved four COVID-19 vaccines for emergency use in a span of two days. The nods were granted to Clover Biopharmaceuticals Ltd., Sinocelltech Group Ltd., Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. and Westvac Biopharma Co. Ltd. There is still no mRNA vaccine approved in the country.
Read More

Regulatory actions for Dec. 8, 2022

Dec. 8, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amarin, Ascletis, Delta-Fly, Moleculin, Novavax, Oncopeptides, Qualigen, Sionna.
Read More

Other news to note for Dec. 8, 2022

Dec. 8, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abiogen, Actinium, Altamedics, Addex, Daiichi Sankyo, Entrada, Gilead, Indivior, Instil, Kite, Revolution, Sanofi, Sensei, Sosei, Spikimm, Tevogen and Vertex.
Read More

Other news to note for Dec. 7, 2022

Dec. 7, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Altavant, Clear Creek, Enzyvant, Equillium, Essential, Everson, Explorna, Hotspot, Intrinsic, Kyowa, MEI, Metrion, Nykode, Omnispirant, Ono, Pfizer, Replimune, Roche, Tris.
Read More

In the clinic for Dec. 7, 2022

Dec. 7, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alzheon, Biovie, Cassava, Celldex, Dragonfly, Editas, Gossamer, Imaginab, Kinarus, Leo, Medicinova, Mirati.
Read More
Respiratory infection
Infection

Tetra reports AI study results of ARDS-003 in combination with favipiravir

Dec. 7, 2022
Tetra Bio-Pharma Inc. has reported results from a study of ARDS-003 (onternabez) combined with favipiravir against acute respiratory distress syndrome (ARDS), sepsis and COVID-19 through PREPAiRE, an artificial intelligence (AI)-powered platform which integrates target identification, validation, lead discovery optimization, drug synthesis and preclinical testing.
Read More
Previous 1 2 … 63 64 65 66 67 68 69 70 71 … 553 554 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 26, 2026.
  • Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

    ENCALS 2026: From genetics to advancing strategies against ALS

    BioWorld Science
    Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
  • Subsense BCI platform

    Next wave of BCI firms builds on pioneers to tackle challenges

    BioWorld
    With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
  • Boehringer Ingelheim identifies new mGlu3 receptor agonists

    BioWorld Science
    Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
  • GT-02897 exerts efficacy in preclinical multiple myeloma

    BioWorld Science
    Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing